factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Uncommitted | preserve | 11-14 | 11-14 | T5 | for | TREATS | 11 | 14 | preserve | 0-10 | 0-10 | T1 | Carvedilol | OrganicChemical | 0 | 10 | preserve | 15-28 | 21-28 | T2 | heart failure | DiseaseOrSyndrome | 15 | 28 | A3 | Carvedilol for heart failure: more than just a beta-blocker? | 0-60 | 0 | 60 | @SUBJECT$ @PREDICAT$ @OBJECT$ : more than just a beta-blocker? |
Probable | preserve | 305-312 | 305-312 | T22 | effects | AFFECTS | 305 | 312 | preserve | 266-276 | 266-276 | T14 | carvedilol | OrganicChemical | 266 | 276 | preserve | 322-335 | 328-335 | T17 | heart failure | DiseaseOrSyndrome | 322 | 335 | A4 | It is suggested that, compared with other beta-blockers, carvedilol has additional advantageous effects in heart failure, and should be considered as part of the routine treatment of heart failure. | 203-418 | 203 | 418 | It is suggested that, compared with other beta-blockers, @SUBJECT$ has additional advantageous @PREDICAT$ in @OBJECT$ , and should be considered as part of the routine treatment of heart failure. |
Fact | preserve | 1741-1750 | 1741-1750 | T110 | treatment | TREATS | 1,741 | 1,750 | preserve | 1790-1798 | 1790-1798 | T109 | estrogen | Hormone | 1,790 | 1,798 | preserve | 1754-1760 | 1754-1760 | T107 | cancer | NeoplasticProcess | 1,754 | 1,760 | A1 | PEP seems to offer a potential for revival of the most cost-effective endocrine treatment of cancer of the prostate, i.e., estrogen. | 1655-1799 | 1,655 | 1,799 | PEP seems to offer a potential for revival of the most cost-effective endocrine @PREDICAT$ of @OBJECT$ of the prostate, i.e., @SUBJECT$ . |
Fact | preserve | 334-338 | 334-338 | T24 | with | PROCESS_OF | 334 | 338 | preserve | 354-373 | 364-373 | T22 | prostatic carcinoma | NeoplasticProcess | 354 | 373 | preserve | 325-333 | 325-333 | T21 | patients | PatientOrDisabledGroup | 325 | 333 | A3 | BACKGROUND: The present pilot study tested the clinical performance of a new pharmacokinetically guided dosing regimen of parenteral estrogen in patients with advanced prostatic carcinoma. | 174-374 | 174 | 374 | BACKGROUND: The present pilot study tested the clinical performance of a new pharmacokinetically guided dosing regimen of parenteral estrogen in @OBJECT$ @PREDICAT$ advanced @SUBJECT$ . |
Fact | preserve | 1600-1616 | 1609-1616 | T99 | estrogen regimen | USES | 1,600 | 1,616 | preserve | 1609-1616 | 1609-1616 | T96 | regimen | ResearchActivity | 1,609 | 1,616 | preserve | 1600-1608 | 1600-1608 | T95 | estrogen | Hormone | 1,600 | 1,608 | A4 | CONCLUSIONS: The present parenteral regimen is an efficient and time-saving estrogen regimen with a favorable side-effect profile. | 1518-1654 | 1,518 | 1,654 | CONCLUSIONS: The present parenteral regimen is an efficient and time-saving @OBJECT$ @PREDICAT$ @SUBJECT$ with a favorable side-effect profile. |
Fact | preserve | 1214-1223 | 1214-1223 | T74 | influence | AFFECTS | 1,214 | 1,223 | preserve | 1203-1213 | 1203-1213 | T67 | estrogenic | Hormone | 1,203 | 1,213 | preserve | 1231-1236 | 1231-1236 | T68 | liver | BodyPartOrganOrOrganComponent | 1,231 | 1,236 | A5 | This was probably due to a minimal estrogenic influence on the liver and was reflected by unchanged levels of coagulation factor VII. | 1162-1307 | 1,162 | 1,307 | This was probably due to a minimal @SUBJECT$ @PREDICAT$ on the @OBJECT$ and was reflected by unchanged levels of coagulation factor VII. |
Fact | preserve | 150-172 | 165-172 | T12 | estrogen regimen | USES | 150 | 172 | preserve | 165-172 | 165-172 | T11 | regimen | ResearchActivity | 165 | 172 | preserve | 150-158 | 150-158 | T10 | estrogen | Hormone | 150 | 158 | A6 | Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. | 80-173 | 80 | 173 | Pharmacokinetics, and endocrine and clinical effects, of a parenteral @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Uncommitted | preserve | 37-46 | 37-46 | T5 | treatment | TREATS | 37 | 46 | preserve | 20-29 | 20-29 | T2 | estrogens | Hormone | 20 | 29 | preserve | 59-78 | 69-78 | T4 | prostatic carcinoma | NeoplasticProcess | 59 | 78 | A7 | Time for revival of estrogens in the treatment of advanced prostatic carcinoma? | 0-79 | 0 | 79 | Time for revival of @SUBJECT$ in the @PREDICAT$ of advanced @OBJECT$ ? |
Fact | preserve | 860-868 | 860-868 | T53 | increase | STIMULATES | 860 | 868 | preserve | 775-783 | 775-783 | T43 | estrogen | Hormone | 775 | 783 | preserve | 878-887 | 878-887 | T49 | estradiol | Hormone | 878 | 887 | A9 | The estrogen dosing was calculated by pharmacokinetic modelling to achieve a rapid increase in serum estradiol and thereby a fast decrease in testosterone. | 765-932 | 765 | 932 | The @SUBJECT$ dosing was calculated by pharmacokinetic modelling to achieve a rapid @PREDICAT$ in serum @OBJECT$ and thereby a fast decrease in testosterone. |
Fact | preserve | 1247-1256 | 1253-1256 | T74 | Serum PTH | LOCATION_OF | 1,247 | 1,256 | preserve | 1247-1252 | 1247-1252 | T70 | Serum | BodySubstance | 1,247 | 1,252 | preserve | 1253-1256 | 1253-1256 | T71 | PTH | AminoAcidPeptideOrProtein | 1,253 | 1,256 | A1 | Serum PTH was not increased (mean 34.8 pmol/L). | 1247-1294 | 1,247 | 1,294 | @SUBJECT$ @PREDICAT$ @OBJECT$ was not increased (mean 34.8 pmol/L). |
Fact | preserve | 514-518 | 514-518 | T45 | with | PROCESS_OF | 514 | 518 | preserve | 530-536 | 530-536 | T36 | stroke | DiseaseOrSyndrome | 530 | 536 | preserve | 497-504 | 497-504 | T33 | elderly | AgeGroup | 497 | 504 | A2 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. | 294-579 | 294 | 579 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 @OBJECT$ subjects @PREDICAT$ hemiplegic @SUBJECT$ and 72 age-matched healthy controls. |
Fact | preserve | 311-320 | 311-320 | T41 | influence | AFFECTS | 311 | 320 | preserve | 340-347 | 340-347 | T25 | calcium | BiologicallyActiveSubstance | 340 | 347 | preserve | 372-387 | 377-387 | T27 | bone metabolism | OrganOrTissueFunction | 372 | 387 | A6 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. | 294-579 | 294 | 579 | To elucidate the @PREDICAT$ of increased serum @SUBJECT$ concentration on @OBJECT$ , we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. |
Fact | preserve | 464-466 | 464-466 | T42 | in | LOCATION_OF | 464 | 466 | preserve | 471-489 | 478-489 | T32 | second metacarpals | BodyPartOrganOrOrganComponent | 471 | 489 | preserve | 431-451 | 444-451 | T31 | bone mineral density | LaboratoryOrTestResult | 431 | 451 | A7 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. | 294-579 | 294 | 579 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and @OBJECT$ (BMD) @PREDICAT$ the @SUBJECT$ of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. |
Fact | preserve | 519-536 | 530-536 | T44 | hemiplegic stroke | PROCESS_OF | 519 | 536 | preserve | 530-536 | 530-536 | T36 | stroke | DiseaseOrSyndrome | 530 | 536 | preserve | 519-529 | 519-529 | T35 | hemiplegic | PatientOrDisabledGroup | 519 | 529 | A9 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. | 294-579 | 294 | 579 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with @OBJECT$ @PREDICAT$ @SUBJECT$ and 72 age-matched healthy controls. |
Fact | preserve | 490-492 | 490-492 | T43 | of | PART_OF | 490 | 492 | preserve | 471-489 | 478-489 | T32 | second metacarpals | BodyPartOrganOrOrganComponent | 471 | 489 | preserve | 497-504 | 497-504 | T33 | elderly | AgeGroup | 497 | 504 | A13 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the second metacarpals of 170 elderly subjects with hemiplegic stroke and 72 age-matched healthy controls. | 294-579 | 294 | 579 | To elucidate the influence of increased serum calcium concentration on bone metabolism, we measured serum biochemical indices and bone mineral density (BMD) in the @SUBJECT$ @PREDICAT$ 170 @OBJECT$ subjects with hemiplegic stroke and 72 age-matched healthy controls. |
Fact | preserve | 99-114 | 106-114 | T10 | stroke patients | PROCESS_OF | 99 | 114 | preserve | 99-105 | 99-105 | T7 | stroke | DiseaseOrSyndrome | 99 | 105 | preserve | 106-114 | 106-114 | T8 | patients | PatientOrDisabledGroup | 106 | 114 | A14 | Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly stroke patients. | 0-115 | 0 | 115 | Effect of immobilization upon renal synthesis of 1,25-dihydroxyvitamin D in disabled elderly @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 271-292 | 284-292 | T21 | stroke patients | PROCESS_OF | 271 | 292 | preserve | 271-277 | 271-277 | T19 | stroke | DiseaseOrSyndrome | 271 | 277 | preserve | 284-292 | 284-292 | T20 | patients | PatientOrDisabledGroup | 284 | 292 | A15 | A 1,25-dihydroxyvitamin D [1,25-(OH)2D] deficiency and immobilization-related increased serum calcium concentration have been observed in hemiplegic stroke patients. | 116-293 | 116 | 293 | A 1,25-dihydroxyvitamin D [1,25-(OH)2D] deficiency and immobilization-related increased serum calcium concentration have been observed in hemiplegic @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1537-1539 | 1537-1539 | T90 | of | LOCATION_OF | 1,537 | 1,539 | preserve | 1550-1567 | 1557-1567 | T85 | second metacarpal | BodyPartOrganOrOrganComponent | 1,550 | 1,567 | preserve | 1533-1536 | 1533-1536 | T84 | BMD | LaboratoryOrTestResult | 1,533 | 1,536 | A16 | BMD of the second metacarpal in patients was decreased significantly compared with control subjects and highly correlated with 25-(OH)D and 1,25-(OH)2D concentrations. | 1533-1718 | 1,533 | 1,718 | @OBJECT$ @PREDICAT$ the @SUBJECT$ in patients was decreased significantly compared with control subjects and highly correlated with 25-(OH)D and 1,25-(OH)2D concentrations. |
Fact | preserve | 641-644 | 641-644 | T54 | had | PROCESS_OF | 641 | 644 | preserve | 665-673 | 665-673 | T51 | response | ClinicalAttribute | 665 | 673 | preserve | 595-603 | 595-603 | T47 | patients | PatientOrDisabledGroup | 595 | 603 | A1 | PATIENTS: 234 patients with active rheumatoid arthritis who had an inadequate response to disease-modifying antirheumatic drugs. | 581-715 | 581 | 715 | PATIENTS: 234 @OBJECT$ with active rheumatoid arthritis who @PREDICAT$ an inadequate @SUBJECT$ to disease-modifying antirheumatic drugs. |
Fact | preserve | 339-357 | 350-357 | T35 | etanercept therapy | TREATS | 339 | 357 | preserve | 339-349 | 339-349 | T25 | etanercept | AminoAcidPeptideOrProtein | 339 | 349 | preserve | 408-416 | 408-416 | T28 | patients | PatientOrDisabledGroup | 408 | 416 | A2 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. | 296-443 | 296 | 443 | OBJECTIVE: To confirm the benefit of @SUBJECT$ @PREDICAT$ of longer duration and simplified dosing in @OBJECT$ with rheumatoid arthritis. |
Fact | preserve | 2069-2071 | 2069-2071 | T146 | in | TREATS | 2,069 | 2,071 | preserve | 1990-2000 | 1990-2000 | T138 | Etanercept | AminoAcidPeptideOrProtein | 1,990 | 2,000 | preserve | 2072-2080 | 2072-2080 | T143 | patients | PatientOrDisabledGroup | 2,072 | 2,080 | A3 | CONCLUSIONS: Etanercept can safely provide rapid, significant, and sustained benefit in patients with active rheumatoid arthritis. | 1977-2120 | 1,977 | 2,120 | CONCLUSIONS: @SUBJECT$ can safely provide rapid, significant, and sustained benefit @PREDICAT$ @OBJECT$ with active rheumatoid arthritis. |
Probable | preserve | 399-401 | 399-401 | T32 | in | TREATS | 399 | 401 | preserve | 350-357 | 350-357 | T26 | therapy | TherapeuticOrPreventiveProcedure | 350 | 357 | preserve | 422-442 | 433-442 | T29 | rheumatoid arthritis | DiseaseOrSyndrome | 422 | 442 | A4 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. | 296-443 | 296 | 443 | OBJECTIVE: To confirm the benefit of etanercept @SUBJECT$ of longer duration and simplified dosing @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 604-608 | 604-608 | T53 | with | PROCESS_OF | 604 | 608 | preserve | 616-636 | 627-636 | T49 | rheumatoid arthritis | DiseaseOrSyndrome | 616 | 636 | preserve | 595-603 | 595-603 | T47 | patients | PatientOrDisabledGroup | 595 | 603 | A6 | PATIENTS: 234 patients with active rheumatoid arthritis who had an inadequate response to disease-modifying antirheumatic drugs. | 581-715 | 581 | 715 | PATIENTS: 234 @OBJECT$ @PREDICAT$ active @SUBJECT$ who had an inadequate response to disease-modifying antirheumatic drugs. |
Fact | preserve | 0-18 | 11-18 | T4 | Etanercept therapy | ISA | 0 | 18 | preserve | 0-10 | 0-10 | T1 | Etanercept | AminoAcidPeptideOrProtein | 0 | 10 | preserve | 11-18 | 11-18 | T2 | therapy | TherapeuticOrPreventiveProcedure | 11 | 18 | A7 | Etanercept therapy in rheumatoid arthritis. | 0-43 | 0 | 43 | @SUBJECT$ @PREDICAT$ @OBJECT$ in rheumatoid arthritis. |
Fact | preserve | 339-357 | 350-357 | T31 | etanercept therapy | USES | 339 | 357 | preserve | 350-357 | 350-357 | T26 | therapy | TherapeuticOrPreventiveProcedure | 350 | 357 | preserve | 339-349 | 339-349 | T25 | etanercept | AminoAcidPeptideOrProtein | 339 | 349 | A8 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. | 296-443 | 296 | 443 | OBJECTIVE: To confirm the benefit of @OBJECT$ @PREDICAT$ @SUBJECT$ of longer duration and simplified dosing in patients with rheumatoid arthritis. |
Fact | preserve | 2069-2071 | 2069-2071 | T146 | in | TREATS | 2,069 | 2,071 | preserve | 1990-2000 | 1990-2000 | T138 | Etanercept | AminoAcidPeptideOrProtein | 1,990 | 2,000 | preserve | 2099-2119 | 2110-2119 | T145 | rheumatoid arthritis | DiseaseOrSyndrome | 2,099 | 2,119 | A9 | CONCLUSIONS: Etanercept can safely provide rapid, significant, and sustained benefit in patients with active rheumatoid arthritis. | 1977-2120 | 1,977 | 2,120 | CONCLUSIONS: @SUBJECT$ can safely provide rapid, significant, and sustained benefit @PREDICAT$ patients with active @OBJECT$ . |
Probable | preserve | 399-401 | 399-401 | T32 | in | TREATS | 399 | 401 | preserve | 350-357 | 350-357 | T26 | therapy | TherapeuticOrPreventiveProcedure | 350 | 357 | preserve | 408-416 | 408-416 | T28 | patients | PatientOrDisabledGroup | 408 | 416 | A11 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. | 296-443 | 296 | 443 | OBJECTIVE: To confirm the benefit of etanercept @SUBJECT$ of longer duration and simplified dosing @PREDICAT$ @OBJECT$ with rheumatoid arthritis. |
Uncommitted | preserve | 19-21 | 19-21 | T6 | in | TREATS | 19 | 21 | preserve | 11-18 | 11-18 | T2 | therapy | TherapeuticOrPreventiveProcedure | 11 | 18 | preserve | 22-42 | 33-42 | T3 | rheumatoid arthritis | DiseaseOrSyndrome | 22 | 42 | A14 | Etanercept therapy in rheumatoid arthritis. | 0-43 | 0 | 43 | Etanercept @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 339-357 | 350-357 | T30 | etanercept therapy | ISA | 339 | 357 | preserve | 339-349 | 339-349 | T25 | etanercept | AminoAcidPeptideOrProtein | 339 | 349 | preserve | 350-357 | 350-357 | T26 | therapy | TherapeuticOrPreventiveProcedure | 350 | 357 | A16 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. | 296-443 | 296 | 443 | OBJECTIVE: To confirm the benefit of @SUBJECT$ @PREDICAT$ @OBJECT$ of longer duration and simplified dosing in patients with rheumatoid arthritis. |
Fact | preserve | 417-421 | 417-421 | T33 | with | PROCESS_OF | 417 | 421 | preserve | 422-442 | 433-442 | T29 | rheumatoid arthritis | DiseaseOrSyndrome | 422 | 442 | preserve | 408-416 | 408-416 | T28 | patients | PatientOrDisabledGroup | 408 | 416 | A18 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in patients with rheumatoid arthritis. | 296-443 | 296 | 443 | OBJECTIVE: To confirm the benefit of etanercept therapy of longer duration and simplified dosing in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 0-18 | 11-18 | T5 | Etanercept therapy | USES | 0 | 18 | preserve | 11-18 | 11-18 | T2 | therapy | TherapeuticOrPreventiveProcedure | 11 | 18 | preserve | 0-10 | 0-10 | T1 | Etanercept | AminoAcidPeptideOrProtein | 0 | 10 | A19 | Etanercept therapy in rheumatoid arthritis. | 0-43 | 0 | 43 | @OBJECT$ @PREDICAT$ @SUBJECT$ in rheumatoid arthritis. |
Fact | preserve | 2081-2085 | 2081-2085 | T147 | with | PROCESS_OF | 2,081 | 2,085 | preserve | 2099-2119 | 2110-2119 | T145 | rheumatoid arthritis | DiseaseOrSyndrome | 2,099 | 2,119 | preserve | 2072-2080 | 2072-2080 | T143 | patients | PatientOrDisabledGroup | 2,072 | 2,080 | A20 | CONCLUSIONS: Etanercept can safely provide rapid, significant, and sustained benefit in patients with active rheumatoid arthritis. | 1977-2120 | 1,977 | 2,120 | CONCLUSIONS: Etanercept can safely provide rapid, significant, and sustained benefit in @OBJECT$ @PREDICAT$ active @SUBJECT$ . |
Uncommitted | preserve | 0-18 | 11-18 | T8 | Etanercept therapy | TREATS | 0 | 18 | preserve | 0-10 | 0-10 | T1 | Etanercept | AminoAcidPeptideOrProtein | 0 | 10 | preserve | 22-42 | 33-42 | T3 | rheumatoid arthritis | DiseaseOrSyndrome | 22 | 42 | A21 | Etanercept therapy in rheumatoid arthritis. | 0-43 | 0 | 43 | @SUBJECT$ @PREDICAT$ in @OBJECT$ . |
Probable | preserve | 1813-1822 | 1813-1822 | T113 | treatment | TREATS | 1,813 | 1,822 | preserve | 1781-1792 | 1781-1792 | T104 | sumatriptan | OrganicChemical | 1,781 | 1,792 | preserve | 1841-1847 | 1841-1847 | T108 | attack | Finding | 1,841 | 1,847 | A1 | These findings suggest that sumatriptan is effective in the treatment of migraine attack, but it must be used with caution in migraines with concomitant hypertension. | 1747-1931 | 1,747 | 1,931 | These findings suggest that @SUBJECT$ is effective in the @PREDICAT$ of migraine @OBJECT$ , but it must be used with caution in migraines with concomitant hypertension. |
Fact | preserve | 55-57 | 55-57 | T7 | in | TREATS | 55 | 57 | preserve | 23-34 | 23-34 | T3 | sumatriptan | OrganicChemical | 23 | 34 | preserve | 58-67 | 58-67 | T6 | migraines | DiseaseOrSyndrome | 58 | 67 | A2 | Effect of subcutaneous sumatriptan on head temperature in migraines. | 0-68 | 0 | 68 | Effect of subcutaneous @SUBJECT$ on head temperature @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1073-1104 | 1096-1104 | T79 | head temperature decrease | LOCATION_OF | 1,073 | 1,104 | preserve | 1073-1077 | 1073-1077 | T68 | head | BodyPartOrganOrOrganComponent | 1,073 | 1,077 | preserve | 1084-1104 | 1096-1104 | T69 | temperature decrease | Finding | 1,084 | 1,104 | A3 | A significant head temperature decrease was observed after s.c. | 1059-1128 | 1,059 | 1,128 | A significant @SUBJECT$ @PREDICAT$ @OBJECT$ was observed after s.c. |
Fact | preserve | 1781-1822 | 1796-1805 | T112 | sumatriptan is effective in the treatment | ISA | 1,781 | 1,822 | preserve | 1781-1792 | 1781-1792 | T104 | sumatriptan | OrganicChemical | 1,781 | 1,792 | preserve | 1813-1822 | 1813-1822 | T106 | treatment | TherapeuticOrPreventiveProcedure | 1,813 | 1,822 | A5 | These findings suggest that sumatriptan is effective in the treatment of migraine attack, but it must be used with caution in migraines with concomitant hypertension. | 1747-1931 | 1,747 | 1,931 | These findings suggest that @SUBJECT$ @PREDICAT$ @OBJECT$ of migraine attack, but it must be used with caution in migraines with concomitant hypertension. |
Fact | preserve | 396-403 | 396-403 | T41 | effects | AFFECTS | 396 | 403 | preserve | 459-470 | 459-470 | T32 | sumatriptan | OrganicChemical | 459 | 470 | preserve | 387-395 | 387-395 | T26 | vascular | BodyPartOrganOrOrganComponent | 387 | 395 | A6 | In view of this we investigated the vascular effects of the standard 6 mg subcutaneous (s.c.) dose of sumatriptan, on the surface areas of the head using thermography, a simple and reliable method for detecting temperature changes. | 351-601 | 351 | 601 | In view of this we investigated the @OBJECT$ @PREDICAT$ of the standard 6 mg subcutaneous (s.c.) dose of @SUBJECT$ , on the surface areas of the head using thermography, a simple and reliable method for detecting temperature changes. |
Fact | preserve | 777-782 | 777-782 | T61 | using | ADMINISTERED_TO | 777 | 782 | preserve | 783-795 | 783-795 | T53 | thermography | DiagnosticProcedure | 783 | 795 | preserve | 630-638 | 630-638 | T45 | patients | PatientOrDisabledGroup | 630 | 638 | A8 | The head temperature of 127 patients (double-blind), 102 migraines (52 during headache attack and 50 headache-free) and 25 healthy control subjects were evaluated using thermography in basal condition and 30, 60, 90, and 120 min after s.c. | 602-859 | 602 | 859 | The head temperature of 127 @OBJECT$ (double-blind), 102 migraines (52 during headache attack and 50 headache-free) and 25 healthy control subjects were evaluated @PREDICAT$ @SUBJECT$ in basal condition and 30, 60, 90, and 120 min after s.c. |
Fact | preserve | 1284-1301 | 1293-1301 | T89 | migraine patients | PROCESS_OF | 1,284 | 1,301 | preserve | 1284-1292 | 1284-1292 | T80 | migraine | DiseaseOrSyndrome | 1,284 | 1,292 | preserve | 1293-1301 | 1293-1301 | T81 | patients | PatientOrDisabledGroup | 1,293 | 1,301 | A10 | In migraine patients during headache attack, head temperature reduction corresponded to the relief of headache symptoms. | 1281-1407 | 1,281 | 1,407 | In @SUBJECT$ @PREDICAT$ @OBJECT$ during headache attack, head temperature reduction corresponded to the relief of headache symptoms. |
Fact | preserve | 178-187 | 178-187 | T17 | treatment | TREATS | 178 | 187 | preserve | 69-80 | 69-80 | T8 | Sumatriptan | OrganicChemical | 69 | 80 | preserve | 197-205 | 197-205 | T16 | migraine | DiseaseOrSyndrome | 197 | 205 | A11 | Sumatriptan, a selective 5-hydroxy-triptamine (5-HT1) receptor agonist, has been used recently in the treatment of acute migraine. | 69-206 | 69 | 206 | @SUBJECT$ , a selective 5-hydroxy-triptamine (5-HT1) receptor agonist, has been used recently in the @PREDICAT$ of acute @OBJECT$ . |
Fact | preserve | 601-603 | 601-603 | T40 | in | TREATS | 601 | 603 | preserve | 598-600 | 598-600 | T36 | CE | TherapeuticOrPreventiveProcedure | 598 | 600 | preserve | 613-621 | 613-621 | T38 | patients | PatientOrDisabledGroup | 613 | 621 | A1 | This review examines the outcomes of early CE in selected patients after a nondisabling stroke. | 549-650 | 549 | 650 | This review examines the outcomes of early @SUBJECT$ @PREDICAT$ selected @OBJECT$ after a nondisabling stroke. |
Fact | preserve | 29-31 | 29-31 | T7 | in | TREATS | 29 | 31 | preserve | 6-28 | 14-28 | T2 | carotid endarterectomy | TherapeuticOrPreventiveProcedure | 6 | 28 | preserve | 48-56 | 48-56 | T5 | patients | PatientOrDisabledGroup | 48 | 56 | A2 | Early carotid endarterectomy in selected stroke patients. | 0-57 | 0 | 57 | Early @SUBJECT$ @PREDICAT$ selected stroke @OBJECT$ . |
Fact | preserve | 41-56 | 48-56 | T6 | stroke patients | PROCESS_OF | 41 | 56 | preserve | 41-47 | 41-47 | T4 | stroke | DiseaseOrSyndrome | 41 | 47 | preserve | 48-56 | 48-56 | T5 | patients | PatientOrDisabledGroup | 48 | 56 | A3 | Early carotid endarterectomy in selected stroke patients. | 0-57 | 0 | 57 | Early carotid endarterectomy in selected @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 29-31 | 29-31 | T7 | in | TREATS | 29 | 31 | preserve | 6-28 | 14-28 | T2 | carotid endarterectomy | TherapeuticOrPreventiveProcedure | 6 | 28 | preserve | 41-47 | 41-47 | T4 | stroke | DiseaseOrSyndrome | 41 | 47 | A4 | Early carotid endarterectomy in selected stroke patients. | 0-57 | 0 | 57 | Early @SUBJECT$ @PREDICAT$ selected @OBJECT$ patients. |
Probable | preserve | 1158-1167 | 1158-1167 | T68 | performed | ADMINISTERED_TO | 1,158 | 1,167 | preserve | 1142-1144 | 1142-1144 | T63 | CE | TherapeuticOrPreventiveProcedure | 1,142 | 1,144 | preserve | 1180-1188 | 1180-1188 | T65 | patients | PatientOrDisabledGroup | 1,180 | 1,188 | A5 | This review suggests that early CE can be performed in selected patients with an acceptable perioperative morbidity and mortality. | 1110-1252 | 1,110 | 1,252 | This review suggests that early @SUBJECT$ can be @PREDICAT$ in selected @OBJECT$ with an acceptable perioperative morbidity and mortality. |
Counterfact | preserve | 1374-1381 | 1374-1381 | T98 | develop | PROCESS_OF | 1,374 | 1,381 | preserve | 1388-1401 | 1396-1401 | T97 | ovarian cysts | DiseaseOrSyndrome | 1,388 | 1,401 | preserve | 1242-1250 | 1242-1250 | T89 | patients | PatientOrDisabledGroup | 1,242 | 1,250 | A2 | All patients after high-dose chemotherapy or older than 50 years had E2 < 0.10 nmol l(-1) and/or amenorrhoea > 1 year and did not develop ovarian cysts. | 1238-1402 | 1,238 | 1,402 | All @OBJECT$ after high-dose chemotherapy or older than 50 years had E2 < 0.10 nmol l(-1) and/or amenorrhoea > 1 year and did not @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 525-544 | 535-544 | T44 | tamoxifen treatment | ISA | 525 | 544 | preserve | 525-534 | 525-534 | T42 | tamoxifen | OrganicChemical | 525 | 534 | preserve | 535-544 | 535-544 | T43 | treatment | TherapeuticOrPreventiveProcedure | 535 | 544 | A3 | Forty-five patients were also examined prior to tamoxifen treatment. | 477-545 | 477 | 545 | Forty-five patients were also examined prior to @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1107-1111 | 1107-1111 | T88 | with | PROCESS_OF | 1,107 | 1,111 | preserve | 1112-1131 | 1126-1131 | T81 | ovarian cysts | DiseaseOrSyndrome | 1,112 | 1,131 | preserve | 1098-1106 | 1098-1106 | T80 | Patients | PatientOrDisabledGroup | 1,098 | 1,106 | A4 | Patients with ovarian cysts had higher serum E2 levels compared to patients without cysts (1.95 vs 0.05 nmol l(-1); P < 0.001). | 1098-1237 | 1,098 | 1,237 | @OBJECT$ @PREDICAT$ @SUBJECT$ had higher serum E2 levels compared to patients without cysts (1.95 vs 0.05 nmol l(-1); P < 0.001). |
Fact | preserve | 336-338 | 336-338 | T31 | in | PROCESS_OF | 336 | 338 | preserve | 313-325 | 321-325 | T26 | ovarian cyst | DiseaseOrSyndrome | 313 | 325 | preserve | 339-344 | 339-344 | T28 | women | PopulationGroup | 339 | 344 | A5 | The present study aimed to evaluate patient-related parameters that determine ovarian cyst formation in women using tamoxifen for breast cancer. | 229-379 | 229 | 379 | The present study aimed to evaluate patient-related parameters that determine @SUBJECT$ formation @PREDICAT$ @OBJECT$ using tamoxifen for breast cancer. |
Fact | preserve | 1519-1541 | 1533-1541 | T115 | Breast cancer patients | PROCESS_OF | 1,519 | 1,541 | preserve | 1519-1532 | 1526-1532 | T106 | Breast cancer | NeoplasticProcess | 1,519 | 1,532 | preserve | 1533-1541 | 1533-1541 | T107 | patients | PatientOrDisabledGroup | 1,533 | 1,541 | A6 | Breast cancer patients receiving tamoxifen only develop ovarian cysts if their ovaries are able to respond to FSH stimulation as shown by E2 production. | 1519-1684 | 1,519 | 1,684 | @SUBJECT$ @PREDICAT$ @OBJECT$ receiving tamoxifen only develop ovarian cysts if their ovaries are able to respond to FSH stimulation as shown by E2 production. |
Fact | preserve | 345-350 | 345-350 | T32 | using | ADMINISTERED_TO | 345 | 350 | preserve | 351-360 | 351-360 | T29 | tamoxifen | OrganicChemical | 351 | 360 | preserve | 339-344 | 339-344 | T28 | women | PopulationGroup | 339 | 344 | A7 | The present study aimed to evaluate patient-related parameters that determine ovarian cyst formation in women using tamoxifen for breast cancer. | 229-379 | 229 | 379 | The present study aimed to evaluate patient-related parameters that determine ovarian cyst formation in @OBJECT$ @PREDICAT$ @SUBJECT$ for breast cancer. |
Fact | preserve | 431-453 | 445-453 | T38 | breast cancer patients | PROCESS_OF | 431 | 453 | preserve | 431-444 | 438-444 | T35 | breast cancer | NeoplasticProcess | 431 | 444 | preserve | 445-453 | 445-453 | T36 | patients | PatientOrDisabledGroup | 445 | 453 | A10 | A cross-sectional study was performed in 142 breast cancer patients using tamoxifen. | 380-476 | 380 | 476 | A cross-sectional study was performed in 142 @SUBJECT$ @PREDICAT$ @OBJECT$ using tamoxifen. |
Fact | preserve | 849-851 | 849-851 | T67 | in | TREATS | 849 | 851 | preserve | 820-829 | 820-829 | T60 | tamoxifen | OrganicChemical | 820 | 829 | preserve | 836-844 | 836-844 | T61 | patients | PatientOrDisabledGroup | 836 | 844 | A11 | Uni- or bilateral ovarian cysts were detected by TVU in 24 tamoxifen-using patients and in one patient before tamoxifen treatment. | 755-897 | 755 | 897 | Uni- or bilateral ovarian cysts were detected by TVU in 24 @SUBJECT$ -using @OBJECT$ and @PREDICAT$ one patient before tamoxifen treatment. |
Fact | preserve | 190-209 | 200-209 | T19 | tamoxifen treatment | USES | 190 | 209 | preserve | 200-209 | 200-209 | T17 | treatment | TherapeuticOrPreventiveProcedure | 200 | 209 | preserve | 190-199 | 190-199 | T16 | tamoxifen | OrganicChemical | 190 | 199 | A13 | Only recently, ovarian cyst formation during tamoxifen treatment has been reported. | 139-228 | 139 | 228 | Only recently, ovarian cyst formation during @OBJECT$ @PREDICAT$ @SUBJECT$ has been reported. |
Fact | preserve | 23-32 | 23-32 | T6 | receiving | ADMINISTERED_TO | 23 | 32 | preserve | 33-42 | 33-42 | T3 | tamoxifen | OrganicChemical | 33 | 42 | preserve | 17-22 | 17-22 | T2 | women | PopulationGroup | 17 | 22 | A14 | Ovarian cysts in women receiving tamoxifen for breast cancer. | 0-61 | 0 | 61 | Ovarian cysts in @OBJECT$ @PREDICAT$ @SUBJECT$ for breast cancer. |
Fact | preserve | 1418-1424 | 1418-1424 | T105 | having | PROCESS_OF | 1,418 | 1,424 | preserve | 1427-1442 | 1437-1442 | T100 | menstrual cycle | OrganismFunction | 1,427 | 1,442 | preserve | 1403-1411 | 1403-1411 | T99 | Patients | PatientOrDisabledGroup | 1,403 | 1,411 | A15 | Patients still having a menstrual cycle during tamoxifen had a high chance (81%) of developing ovarian cysts. | 1403-1518 | 1,403 | 1,518 | @OBJECT$ still @PREDICAT$ a @SUBJECT$ during tamoxifen had a high chance (81%) of developing ovarian cysts. |
Fact | preserve | 877-896 | 887-896 | T69 | tamoxifen treatment | USES | 877 | 896 | preserve | 877-886 | 877-886 | T64 | tamoxifen | OrganicChemical | 877 | 886 | preserve | 877-886 | 877-886 | T64 | tamoxifen | OrganicChemical | 877 | 886 | A16 | Uni- or bilateral ovarian cysts were detected by TVU in 24 tamoxifen-using patients and in one patient before tamoxifen treatment. | 755-897 | 755 | 897 | Uni- or bilateral ovarian cysts were detected by TVU in 24 tamoxifen-using patients and in one patient before @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 454-459 | 454-459 | T39 | using | ADMINISTERED_TO | 454 | 459 | preserve | 466-475 | 466-475 | T37 | tamoxifen | OrganicChemical | 466 | 475 | preserve | 445-453 | 445-453 | T36 | patients | PatientOrDisabledGroup | 445 | 453 | A17 | A cross-sectional study was performed in 142 breast cancer patients using tamoxifen. | 380-476 | 380 | 476 | A cross-sectional study was performed in 142 breast cancer @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 14-16 | 14-16 | T5 | in | PROCESS_OF | 14 | 16 | preserve | 0-13 | 8-13 | T1 | Ovarian cysts | DiseaseOrSyndrome | 0 | 13 | preserve | 17-22 | 17-22 | T2 | women | PopulationGroup | 17 | 22 | A18 | Ovarian cysts in women receiving tamoxifen for breast cancer. | 0-61 | 0 | 61 | @SUBJECT$ @PREDICAT$ @OBJECT$ receiving tamoxifen for breast cancer. |
Fact | preserve | 525-544 | 535-544 | T45 | tamoxifen treatment | USES | 525 | 544 | preserve | 535-544 | 535-544 | T43 | treatment | TherapeuticOrPreventiveProcedure | 535 | 544 | preserve | 525-534 | 525-534 | T42 | tamoxifen | OrganicChemical | 525 | 534 | A19 | Forty-five patients were also examined prior to tamoxifen treatment. | 477-545 | 477 | 545 | Forty-five patients were also examined prior to @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 43-46 | 43-46 | T7 | for | TREATS | 43 | 46 | preserve | 33-42 | 33-42 | T3 | tamoxifen | OrganicChemical | 33 | 42 | preserve | 47-60 | 54-60 | T4 | breast cancer | NeoplasticProcess | 47 | 60 | A20 | Ovarian cysts in women receiving tamoxifen for breast cancer. | 0-61 | 0 | 61 | Ovarian cysts in women receiving @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1542-1551 | 1542-1551 | T116 | receiving | ADMINISTERED_TO | 1,542 | 1,551 | preserve | 1558-1567 | 1558-1567 | T108 | tamoxifen | OrganicChemical | 1,558 | 1,567 | preserve | 1533-1541 | 1533-1541 | T107 | patients | PatientOrDisabledGroup | 1,533 | 1,541 | A21 | Breast cancer patients receiving tamoxifen only develop ovarian cysts if their ovaries are able to respond to FSH stimulation as shown by E2 production. | 1519-1684 | 1,519 | 1,684 | Breast cancer @OBJECT$ @PREDICAT$ @SUBJECT$ only develop ovarian cysts if their ovaries are able to respond to FSH stimulation as shown by E2 production. |
Fact | preserve | 1635-1657 | 1646-1657 | T117 | FSH stimulation | USES | 1,635 | 1,657 | preserve | 1646-1657 | 1646-1657 | T113 | stimulation | TherapeuticOrPreventiveProcedure | 1,646 | 1,657 | preserve | 1635-1638 | 1635-1638 | T112 | FSH | AminoAcidPeptideOrProtein | 1,635 | 1,638 | A22 | Breast cancer patients receiving tamoxifen only develop ovarian cysts if their ovaries are able to respond to FSH stimulation as shown by E2 production. | 1519-1684 | 1,519 | 1,684 | Breast cancer patients receiving tamoxifen only develop ovarian cysts if their ovaries are able to respond to @OBJECT$ @PREDICAT$ @SUBJECT$ as shown by E2 production. |
Fact | preserve | 361-364 | 361-364 | T33 | for | TREATS | 361 | 364 | preserve | 351-360 | 351-360 | T29 | tamoxifen | OrganicChemical | 351 | 360 | preserve | 365-378 | 372-378 | T30 | breast cancer | NeoplasticProcess | 365 | 378 | A23 | The present study aimed to evaluate patient-related parameters that determine ovarian cyst formation in women using tamoxifen for breast cancer. | 229-379 | 229 | 379 | The present study aimed to evaluate patient-related parameters that determine ovarian cyst formation in women using @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 190-209 | 200-209 | T18 | tamoxifen treatment | ISA | 190 | 209 | preserve | 190-199 | 190-199 | T16 | tamoxifen | OrganicChemical | 190 | 199 | preserve | 200-209 | 200-209 | T17 | treatment | TherapeuticOrPreventiveProcedure | 200 | 209 | A24 | Only recently, ovarian cyst formation during tamoxifen treatment has been reported. | 139-228 | 139 | 228 | Only recently, ovarian cyst formation during @SUBJECT$ @PREDICAT$ @OBJECT$ has been reported. |
Fact | preserve | 877-896 | 887-896 | T66 | tamoxifen treatment | ISA | 877 | 896 | preserve | 877-886 | 877-886 | T64 | tamoxifen | OrganicChemical | 877 | 886 | preserve | 887-896 | 887-896 | T65 | treatment | TherapeuticOrPreventiveProcedure | 887 | 896 | A26 | Uni- or bilateral ovarian cysts were detected by TVU in 24 tamoxifen-using patients and in one patient before tamoxifen treatment. | 755-897 | 755 | 897 | Uni- or bilateral ovarian cysts were detected by TVU in 24 tamoxifen-using patients and in one patient before @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 568-570 | 568-570 | T30 | in | TREATS | 568 | 570 | preserve | 495-513 | 503-513 | T24 | calcium antagonist | PharmacologicSubstance | 495 | 513 | preserve | 580-619 | 612-619 | T28 | hypertensive target organ disease | DiseaseOrSyndrome | 580 | 619 | A1 | Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonist combinations should be particularly efficacious in reducing hypertensive target organ disease. | 444-620 | 444 | 620 | Angiotensin-converting enzyme (ACE) inhibitors and @SUBJECT$ combinations should be particularly efficacious @PREDICAT$ reducing @OBJECT$ . |
Fact | preserve | 966-970 | 966-970 | T52 | with | PROCESS_OF | 966 | 970 | preserve | 971-993 | 986-993 | T47 | coronary heart disease | DiseaseOrSyndrome | 971 | 993 | preserve | 957-965 | 957-965 | T46 | patients | PatientOrDisabledGroup | 957 | 965 | A2 | However, their use together in left ventricular hypertrophy and in patients with coronary heart disease, although promising, must be proved through carefully designed, prospective, randomized trials. | 883-1095 | 883 | 1,095 | However, their use together in left ventricular hypertrophy and in @OBJECT$ @PREDICAT$ @SUBJECT$ , although promising, must be proved through carefully designed, prospective, randomized trials. |
Fact | preserve | 728-753 | 742-753 | T38 | renal disease progression | LOCATION_OF | 728 | 753 | preserve | 728-733 | 728-733 | T36 | renal | BodyPartOrganOrOrganComponent | 728 | 733 | preserve | 734-753 | 742-753 | T37 | disease progression | PathologicFunction | 734 | 753 | A3 | Both of these drug classes have been shown to reduce complications of hypertensive heart disease and renal disease progression. | 621-754 | 621 | 754 | Both of these drug classes have been shown to reduce complications of hypertensive heart disease and @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 356-365 | 356-365 | T22 | treatment | TREATS | 356 | 365 | preserve | 323-342 | 335-342 | T18 | combination therapy | TherapeuticOrPreventiveProcedure | 323 | 342 | preserve | 369-381 | 369-381 | T20 | hypertension | DiseaseOrSyndrome | 369 | 381 | A4 | Therefore, our knowledge of combination therapy in the treatment of hypertension is largely extrapolated from these monotherapy studies. | 295-443 | 295 | 443 | Therefore, our knowledge of @SUBJECT$ in the @PREDICAT$ of @OBJECT$ is largely extrapolated from these monotherapy studies. |
Fact | preserve | 606-619 | 612-619 | T29 | organ disease | LOCATION_OF | 606 | 619 | preserve | 606-611 | 606-611 | T27 | organ | BodyPartOrganOrOrganComponent | 606 | 611 | preserve | 580-619 | 612-619 | T28 | hypertensive target organ disease | DiseaseOrSyndrome | 580 | 619 | A6 | Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonist combinations should be particularly efficacious in reducing hypertensive target organ disease. | 444-620 | 444 | 620 | Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonist combinations should be particularly efficacious in reducing @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 568-570 | 568-570 | T30 | in | TREATS | 568 | 570 | preserve | 444-490 | 480-490 | T23 | Angiotensin-converting enzyme (ACE) inhibitors | PharmacologicSubstance | 444 | 490 | preserve | 580-619 | 612-619 | T28 | hypertensive target organ disease | DiseaseOrSyndrome | 580 | 619 | A7 | Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonist combinations should be particularly efficacious in reducing hypertensive target organ disease. | 444-620 | 444 | 620 | @SUBJECT$ and calcium antagonist combinations should be particularly efficacious @PREDICAT$ reducing @OBJECT$ . |
Fact | preserve | 488-509 | 501-509 | T36 | Hypertensive patients | PROCESS_OF | 488 | 509 | preserve | 488-500 | 488-500 | T28 | Hypertensive | Finding | 488 | 500 | preserve | 501-509 | 501-509 | T29 | patients | PatientOrDisabledGroup | 501 | 509 | A5 | Hypertensive patients with diabetes type II suffering from side effects from ACE-i are frequently changed over to AII-r. | 488-615 | 488 | 615 | @SUBJECT$ @PREDICAT$ @OBJECT$ with diabetes type II suffering from side effects from ACE-i are frequently changed over to AII-r. |
Fact | preserve | 1434-1452 | 1443-1452 | T80 | losartan treatment | ISA | 1,434 | 1,452 | preserve | 1434-1442 | 1434-1442 | T76 | losartan | OrganicChemical | 1,434 | 1,442 | preserve | 1443-1452 | 1443-1452 | T77 | treatment | TherapeuticOrPreventiveProcedure | 1,443 | 1,452 | A6 | Mean arterial pressure (MAP) increased by 4 +/- 5 mm Hg (P <.05) after 6 months of losartan treatment as compared with the point of withdrawal of ACE-i. | 1345-1509 | 1,345 | 1,509 | Mean arterial pressure (MAP) increased by 4 +/- 5 mm Hg (P <.05) after 6 months of @SUBJECT$ @PREDICAT$ @OBJECT$ as compared with the point of withdrawal of ACE-i. |
Fact | preserve | 101-103 | 101-103 | T9 | in | TREATS | 101 | 103 | preserve | 65-100 | 89-100 | T3 | angiotensin-II-receptor antagonists | PharmacologicSubstance | 65 | 100 | preserve | 104-116 | 104-116 | T4 | hypertensive | Finding | 104 | 116 | A7 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences. | 0-203 | 0 | 203 | Replacement of angiotensin-converting enzyme inhibitors by @SUBJECT$ @PREDICAT$ @OBJECT$ patients with type II diabetes mellitus: metabolic and hemodynamic consequences. |
Fact | preserve | 371-379 | 371-379 | T25 | increase | STIMULATES | 371 | 379 | preserve | 365-370 | 365-370 | T19 | ACE-i | PharmacologicSubstance | 365 | 370 | preserve | 390-400 | 390-400 | T21 | bradykinin | AminoAcidPeptideOrProtein | 390 | 400 | A10 | The main pharmacodynamic difference between angiotensin-converting enzyme-inhibitors (ACE-i) and angiotensin-II-receptor antagonists (AII-r) is that ACE-i increase levels of bradykinin, which, in addition to vasodilation, may cause a decrease in insulin resistance. | 204-487 | 204 | 487 | The main pharmacodynamic difference between angiotensin-converting enzyme-inhibitors (ACE-i) and angiotensin-II-receptor antagonists (AII-r) is that @SUBJECT$ @PREDICAT$ levels of @OBJECT$ , which, in addition to vasodilation, may cause a decrease in insulin resistance. |
Fact | preserve | 101-103 | 101-103 | T9 | in | TREATS | 101 | 103 | preserve | 65-100 | 89-100 | T3 | angiotensin-II-receptor antagonists | PharmacologicSubstance | 65 | 100 | preserve | 117-125 | 117-125 | T5 | patients | PatientOrDisabledGroup | 117 | 125 | A11 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences. | 0-203 | 0 | 203 | Replacement of angiotensin-converting enzyme inhibitors by @SUBJECT$ @PREDICAT$ hypertensive @OBJECT$ with type II diabetes mellitus: metabolic and hemodynamic consequences. |
Fact | preserve | 1434-1452 | 1443-1452 | T81 | losartan treatment | USES | 1,434 | 1,452 | preserve | 1443-1452 | 1443-1452 | T77 | treatment | TherapeuticOrPreventiveProcedure | 1,443 | 1,452 | preserve | 1434-1442 | 1434-1442 | T76 | losartan | OrganicChemical | 1,434 | 1,442 | A12 | Mean arterial pressure (MAP) increased by 4 +/- 5 mm Hg (P <.05) after 6 months of losartan treatment as compared with the point of withdrawal of ACE-i. | 1345-1509 | 1,345 | 1,509 | Mean arterial pressure (MAP) increased by 4 +/- 5 mm Hg (P <.05) after 6 months of @OBJECT$ @PREDICAT$ @SUBJECT$ as compared with the point of withdrawal of ACE-i. |
Fact | preserve | 2122-2143 | 2135-2143 | T120 | hypertensive patients | PROCESS_OF | 2,122 | 2,143 | preserve | 2122-2134 | 2122-2134 | T111 | hypertensive | Finding | 2,122 | 2,134 | preserve | 2135-2143 | 2135-2143 | T112 | patients | PatientOrDisabledGroup | 2,135 | 2,143 | A13 | Replacement of ACE-i by AII-r in hypertensive patients with type II diabetes mellitus induced a significant increase in HbA (1c) and MAP and a decrease in FLOW. | 2089-2261 | 2,089 | 2,261 | Replacement of ACE-i by AII-r in @SUBJECT$ @PREDICAT$ @OBJECT$ with type II diabetes mellitus induced a significant increase in HbA (1c) and MAP and a decrease in FLOW. |
Fact | preserve | 104-125 | 117-125 | T8 | hypertensive patients | PROCESS_OF | 104 | 125 | preserve | 104-116 | 104-116 | T4 | hypertensive | Finding | 104 | 116 | preserve | 117-125 | 117-125 | T5 | patients | PatientOrDisabledGroup | 117 | 125 | A14 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences. | 0-203 | 0 | 203 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in @SUBJECT$ @PREDICAT$ @OBJECT$ with type II diabetes mellitus: metabolic and hemodynamic consequences. |
Fact | preserve | 126-130 | 126-130 | T10 | with | PROCESS_OF | 126 | 130 | preserve | 131-162 | 154-162 | T6 | type II diabetes mellitus | DiseaseOrSyndrome | 131 | 162 | preserve | 117-125 | 117-125 | T5 | patients | PatientOrDisabledGroup | 117 | 125 | A15 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences. | 0-203 | 0 | 203 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive @OBJECT$ @PREDICAT$ @SUBJECT$ : metabolic and hemodynamic consequences. |
Fact | preserve | 1008-1015 | 1008-1015 | T64 | treated | TREATS | 1,008 | 1,015 | preserve | 1027-1036 | 1027-1036 | T56 | enalapril | AminoAcidPeptideOrProtein | 1,027 | 1,036 | preserve | 994-1002 | 994-1002 | T55 | patients | PatientOrDisabledGroup | 994 | 1,002 | A16 | Sixteen patients were treated with 10 mg enalapril or equipotent doses of other ACE-i for 6 months and subsequently with the AII-r losartan at 50 mg daily for 6 more months. | 986-1171 | 986 | 1,171 | Sixteen @OBJECT$ were @PREDICAT$ with 10 mg @SUBJECT$ or equipotent doses of other ACE-i for 6 months and subsequently with the AII-r losartan at 50 mg daily for 6 more months. |
Fact | preserve | 101-103 | 101-103 | T9 | in | TREATS | 101 | 103 | preserve | 65-100 | 89-100 | T3 | angiotensin-II-receptor antagonists | PharmacologicSubstance | 65 | 100 | preserve | 131-162 | 154-162 | T6 | type II diabetes mellitus | DiseaseOrSyndrome | 131 | 162 | A17 | Replacement of angiotensin-converting enzyme inhibitors by angiotensin-II-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and hemodynamic consequences. | 0-203 | 0 | 203 | Replacement of angiotensin-converting enzyme inhibitors by @SUBJECT$ @PREDICAT$ hypertensive patients with @OBJECT$ : metabolic and hemodynamic consequences. |
Fact | preserve | 2150-2154 | 2150-2154 | T122 | with | PROCESS_OF | 2,150 | 2,154 | preserve | 2155-2180 | 2172-2180 | T113 | type II diabetes mellitus | DiseaseOrSyndrome | 2,155 | 2,180 | preserve | 2135-2143 | 2135-2143 | T112 | patients | PatientOrDisabledGroup | 2,135 | 2,143 | A18 | Replacement of ACE-i by AII-r in hypertensive patients with type II diabetes mellitus induced a significant increase in HbA (1c) and MAP and a decrease in FLOW. | 2089-2261 | 2,089 | 2,261 | Replacement of ACE-i by AII-r in hypertensive @OBJECT$ @PREDICAT$ @SUBJECT$ induced a significant increase in HbA (1c) and MAP and a decrease in FLOW. |
Fact | preserve | 461-465 | 461-465 | T31 | with | USES | 461 | 465 | preserve | 410-453 | 442-453 | T21 | percutaneous transluminal renal angioplasty | TherapeuticOrPreventiveProcedure | 410 | 453 | preserve | 466-471 | 466-471 | T22 | stent | MedicalDevice | 466 | 471 | A1 | A percutaneous transluminal renal angioplasty (PTRA) with stent significantly improved both renal function and hypertension and the patient was still not on dialysis twelve months after the procedure. | 408-620 | 408 | 620 | A @SUBJECT$ (PTRA) @PREDICAT$ @OBJECT$ significantly improved both renal function and hypertension and the patient was still not on dialysis twelve months after the procedure. |
Probable | preserve | 799-806 | 799-806 | T44 | improve | TREATS | 799 | 806 | preserve | 771-788 | 771-788 | T40 | revascularization | TherapeuticOrPreventiveProcedure | 771 | 788 | preserve | 827-839 | 827-839 | T42 | hypertension | DiseaseOrSyndrome | 827 | 839 | A3 | Treatment consists in the revascularization, this can improve not only the hypertension but also the renal function. | 745-868 | 745 | 868 | Treatment consists in the @SUBJECT$ , this can @PREDICAT$ not only the @OBJECT$ but also the renal function. |
Counterfact | preserve | 1674-1683 | 1674-1683 | T112 | receiving | ADMINISTERED_TO | 1,674 | 1,683 | preserve | 1684-1691 | 1684-1691 | T102 | aspirin | OrganicChemical | 1,684 | 1,691 | preserve | 1638-1643 | 1638-1643 | T100 | woman | PopulationGroup | 1,638 | 1,643 | A1 | Being a woman was associated with not receiving aspirin (OR, 0.78; 95% CI, 0.62-0.98) but was positively associated with receiving lipid-lowering medications (OR, 1.59; 95% CI, 1.04-2.43). | 1630-1836 | 1,630 | 1,836 | Being a @OBJECT$ was associated with not @PREDICAT$ @SUBJECT$ (OR, 0.78; 95% CI, 0.62-0.98) but was positively associated with receiving lipid-lowering medications (OR, 1.59; 95% CI, 1.04-2.43). |
Fact | preserve | 458-461 | 458-461 | T34 | for | TREATS | 458 | 461 | preserve | 442-457 | 442-457 | T31 | hospitalization | HealthCareActivity | 442 | 457 | preserve | 472-480 | 478-480 | T33 | acute MI | DiseaseOrSyndrome | 472 | 480 | A2 | OBJECTIVE: To examine trends in and determinants of receipt of these 3 medications before hospitalization for recurrent acute MI (AMI). | 346-493 | 346 | 493 | OBJECTIVE: To examine trends in and determinants of receipt of these 3 medications before @SUBJECT$ @PREDICAT$ recurrent @OBJECT$ (AMI). |
Fact | preserve | 600-604 | 600-604 | T47 | with | PROCESS_OF | 600 | 604 | preserve | 627-630 | 627-630 | T43 | AMI | DiseaseOrSyndrome | 627 | 630 | preserve | 542-550 | 542-550 | T38 | patients | PatientOrDisabledGroup | 542 | 550 | A3 | METHODS: The study population consisted of 1710 patients with a previous history of MI hospitalized with a validated recurrent AMI in all hospitals in Worcester, Mass, during 1986, 1988, 1990, 1991, 1993, and 1995. | 494-720 | 494 | 720 | METHODS: The study population consisted of 1710 @OBJECT$ with a previous history of MI hospitalized @PREDICAT$ a validated recurrent @SUBJECT$ in all hospitals in Worcester, Mass, during 1986, 1988, 1990, 1991, 1993, and 1995. |
Counterfact | preserve | 1034-1043 | 1034-1043 | T80 | receiving | ADMINISTERED_TO | 1,034 | 1,043 | preserve | 1049-1059 | 1049-1059 | T69 | medication | PharmacologicSubstance | 1,049 | 1,059 | preserve | 997-1005 | 997-1005 | T65 | patients | PatientOrDisabledGroup | 997 | 1,005 | A4 | RESULTS: More than 47% of patients in each study year were not receiving each medication before admission, although significant increases in use were noted over time for aspirin (from 13.5% to 52.6%), beta-blockers (from 33.2% to 44.4%), and lipid-lowering medications (from 0.8% to 11.7%). | 965-1279 | 965 | 1,279 | RESULTS: More than 47% of @OBJECT$ in each study year were not @PREDICAT$ each @SUBJECT$ before admission, although significant increases in use were noted over time for aspirin (from 13.5% to 52.6%), beta-blockers (from 33.2% to 44.4%), and lipid-lowering medications (from 0.8% to 11.7%). |
Fact | preserve | 185-188 | 185-188 | T25 | had | PROCESS_OF | 185 | 188 | preserve | 200-221 | 211-221 | T16 | myocardial infarction | DiseaseOrSyndrome | 200 | 221 | preserve | 167-175 | 167-175 | T14 | patients | PatientOrDisabledGroup | 167 | 175 | A5 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death. | 151-345 | 151 | 345 | BACKGROUND: For @OBJECT$ who have @PREDICAT$ a previous @SUBJECT$ (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death. |
Fact | preserve | 296-312 | 308-312 | T26 | reduces the risk | PREVENTS | 296 | 312 | preserve | 246-253 | 246-253 | T18 | aspirin | OrganicChemical | 246 | 253 | preserve | 332-334 | 332-334 | T23 | MI | DiseaseOrSyndrome | 332 | 334 | A6 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death. | 151-345 | 151 | 345 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of @SUBJECT$ , beta-blockers, and lipid-lowering agents @PREDICAT$ of recurrent @OBJECT$ and death. |
Fact | preserve | 296-312 | 308-312 | T26 | reduces the risk | PREVENTS | 296 | 312 | preserve | 255-268 | 255-268 | T19 | beta-blockers | PharmacologicSubstance | 255 | 268 | preserve | 332-334 | 332-334 | T23 | MI | DiseaseOrSyndrome | 332 | 334 | A7 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death. | 151-345 | 151 | 345 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of aspirin, @SUBJECT$ , and lipid-lowering agents @PREDICAT$ of recurrent @OBJECT$ and death. |
Uncommitted | preserve | 135-138 | 135-138 | T11 | for | USES | 135 | 138 | preserve | 139-149 | 139-149 | T10 | prevention | TherapeuticOrPreventiveProcedure | 139 | 149 | preserve | 16-29 | 16-29 | T3 | beta-blockers | PharmacologicSubstance | 16 | 29 | A8 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? | 0-150 | 0 | 150 | Use of aspirin, @OBJECT$ , and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities @PREDICAT$ @SUBJECT$ ? |
Uncommitted | preserve | 135-138 | 135-138 | T11 | for | USES | 135 | 138 | preserve | 139-149 | 139-149 | T10 | prevention | TherapeuticOrPreventiveProcedure | 139 | 149 | preserve | 50-61 | 50-61 | T6 | medications | PharmacologicSubstance | 50 | 61 | A10 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? | 0-150 | 0 | 150 | Use of aspirin, beta-blockers, and lipid-lowering @OBJECT$ before recurrent acute myocardial infarction: missed opportunities @PREDICAT$ @SUBJECT$ ? |
Uncommitted | preserve | 135-138 | 135-138 | T11 | for | USES | 135 | 138 | preserve | 139-149 | 139-149 | T10 | prevention | TherapeuticOrPreventiveProcedure | 139 | 149 | preserve | 7-14 | 7-14 | T2 | aspirin | OrganicChemical | 7 | 14 | A12 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? | 0-150 | 0 | 150 | Use of @OBJECT$ , beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities @PREDICAT$ @SUBJECT$ ? |
Fact | preserve | 946-949 | 946-949 | T62 | for | TREATS | 946 | 949 | preserve | 927-945 | 936-945 | T59 | hospital admission | HealthCareActivity | 927 | 945 | preserve | 960-963 | 960-963 | T61 | AMI | DiseaseOrSyndrome | 960 | 963 | A13 | Logistic regression analyses were used to assess the effect of demographic, clinical, and temporal factors on the receipt of aspirin, beta-blockers, and lipid-lowering medications before hospital admission for recurrent AMI. | 721-964 | 721 | 964 | Logistic regression analyses were used to assess the effect of demographic, clinical, and temporal factors on the receipt of aspirin, beta-blockers, and lipid-lowering medications before @SUBJECT$ @PREDICAT$ recurrent @OBJECT$ . |
Fact | preserve | 296-312 | 308-312 | T26 | reduces the risk | PREVENTS | 296 | 312 | preserve | 274-295 | 289-295 | T20 | lipid-lowering agents | PharmacologicSubstance | 274 | 295 | preserve | 332-334 | 332-334 | T23 | MI | DiseaseOrSyndrome | 332 | 334 | A14 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death. | 151-345 | 151 | 345 | BACKGROUND: For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and @SUBJECT$ @PREDICAT$ of recurrent @OBJECT$ and death. |
Fact | preserve | 1294-1296 | 1294-1296 | T115 | to | compared_with | 1,294 | 1,296 | preserve | 1263-1273 | 1263-1273 | T97 | Salmeterol | OrganicChemical | 1,263 | 1,273 | preserve | 1297-1309 | 1297-1309 | T99 | theophylline | BiologicallyActiveSubstance | 1,297 | 1,309 | A2 | Salmeterol was superior to theophylline (p < or = 0.05) in maintaining nocturnal FEV1 levels and was superior to placebo (p < or = 0.05) in improving morning and evening peak expiratory flow (PEF) and in decreasing nighttime albuterol use. | 1263-1521 | 1,263 | 1,521 | @SUBJECT$ was superior @PREDICAT$ @OBJECT$ (p < or = 0.05) in maintaining nocturnal FEV1 levels and was superior to placebo (p < or = 0.05) in improving morning and evening peak expiratory flow (PEF) and in decreasing nighttime albuterol use. |